Walter M. Stadler to Imidazoles
This is a "connection" page, showing publications Walter M. Stadler has written about Imidazoles.
Connection Strength
0.703
-
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Target Oncol. 2016 Apr; 11(2):229-34.
Score: 0.126
-
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50.
Score: 0.109
-
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44.
Score: 0.108
-
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013 May; 53(5):491-504.
Score: 0.102
-
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20; 27(27):4462-8.
Score: 0.079
-
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int. 2007 Jul; 100(1):70-5.
Score: 0.069
-
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63.
Score: 0.063
-
Nilutamide: possible utility as a second-line hormonal agent. Urology. 2001 Dec; 58(6):1016-20.
Score: 0.047